Hillstream Biopharma

Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (IMCD) for drug resistant and devastating cancers. It also develops the Trident Artificial Intelligence (TAI) precision medicine platform which is used to identify biomarkers in its clinical programs to target a specific patient segment. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

Quatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs) by inducing ferroptosis in drug resistant cancers

Hillstream BioPharma to Host Virtual R&D Day to Showcase its Emerging Immuno-oncology Pipeline Targeting Drug-Resistant Cancers

It's not every day that you hear about Hillstream BioPharma (NASDAQ: HILS ) in the financial headlines. Today, however, HILS stock is skyrocketing more than 100% on heavy trading volume.

Why Is Hillstream BioPharma (HILS) Stock Up 100% Today?

Context Therapeutics LLC

Intelligent Bio Solutions Inc

Rent the Runway

Silo Pharma Inc

Sonoma Pharmaceuticals

Spectrum Pharma

Penny Stocks With News Light Up The Scanners This Week This week

7 Top Penny Stocks To Watch With Big News This Week

Development expected to capitalize upon tumor targeting Quatramers™

Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers

BRIDGEWATER, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the Virtual Sidoti Micro-Cap Conference being held on January 18-19, 2023.

Hillstream BioPharma to Present at the Virtual Sidoti Micro-Cap Conference on January 18-19, 2023

Akebia Therapeutics

Bone Biologics Corp

HTG Molecular Diagnostics

Kalera PLC

Pagaya Technologies Ltd

SINTX Technologies Inc

Sio Gene Therapies

Venator Materials

Wearable Devices Ltd

Penny stocks to watch trading under $1 right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch

Low float penny stocks under $1 to watch after AMAM stock explodes over 500%. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 3 Low Float Stocks Under $1 To Watch

Collaboration allows Hillstream to enter the rapidly growing Immuno-oncology therapeutics market

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies™ (HSB-1940) against PD-1, by combining Quatramers™ with OmniAb's Picobodies™, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitope

BRIDGEWATER, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will present at the 2022 RHK Capital Disruptive Growth Conference hosted at Reed Smith in New York City on December 5-6, 2022.

Hillstream BioPharma to Present at the RHK Capital Disruptive Growth Conference on December 5-6, 2022

Abstract highlights data from HSB-1216 in acute myeloid leukemia (AML) growth Abstract highlights data from HSB-1216 in acute myeloid leukemia (AML) growth

Hillstream's New Anti-Cancer Mechanism Quatramer-based Ferroptosis Inducer, HSB-1216 Abstract Available for Viewing at EORTC-NCI-AACR Symposium

BRIDGEWATER, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, today announced that Randy Milby, Founder and Chief Executive Officer will present in-person and host one-on-one meetings with investors at the following conferences:

Hillstream BioPharma, Inc. to Present at Upcoming Investor Conferences

BRIDGEWATER, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, will participate in the Fierce Biotech Summit, being held at The Westin Copley Place in Boston, on September 19-20, 2022.

Hillstream BioPharma to Participate in the Fierce Biotech Summit on September 19-20

BRIDGEWATER, N.J., July 08, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, will attend the 12th Annual World Orphan Drug Congress USA 2022, being held at the Hynes Convention Center in Boston, on July 11-13, 2022.

Hillstream BioPharma to Attend the 12th Annual World Orphan Drug Congress USA on July 11-13

Acutus Medical

Agile Therapeutics

Cybin

Evofem Biosciences Inc

Penny stocks to watch with news The post Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why EVFM, AGRX, CYBN, HILS & AFIB Stock Are Moving

Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors Investigating the synergy between HSB-1216, a Ferroptosis inducer, and Immune Checkpoint Inhibitors

Hillstream BioPharma Announces Collaboration with Sapien Biosciences in Cancer Treatments

Hillstream BioPharma Inc (NASDAQ: HILS) shares are trading higher after it authorized a share repurchase program to acquire up to $1 million in common stock.  As of March 31, Hillstream had approximately $11.1 million in cash and 11.4 million shares of common stock.

Why Hillstream BioPharma Shares Are Trading Higher Today?

HILS stock explodes on Monday & here's why. The post Penny Stocks To Watch: Why Hillstream BioPharma (HILS) Is Moving Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why Hillstream BioPharma (HILS) Is Moving Today

BRIDGEWATER, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream,” the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, today provided a corporate update for its investors and a roadmap of clinical studies through 2023.

Hillstream BioPharma Provides Corporate Update

BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ: HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug-resistant and devastating cancers, announced that it is scheduled to present at BioNJ's 12th Annual BioPartnering Virtual Conference , taking place Monday, May 9, 2022, to Friday, May 13, 2022.

Hillstream BioPharma to Present at BioNJ's 12th Annual BioPartnering Virtual Conference Held on May 9- 13, 2022

BRIDGEWATER, NJ, March 02, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ: HILS) ("Hillstream" or the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, provided a webcast replay of the Company's R&D Day held on February 24, 2022.

Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers

- Uveal melanoma is a n aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease -

Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma

Continued development and validation of HSB-1216 as a leading Ferroptosis inducer to enter the clinic Successful Closing of a $15 million Initial Public Offering on January 14, 2022 R&D Day to Review Novel Emerging Pipeline on February 24, 2022 BRIDGEWATER, NJ / ACCESSWIRE / February 14, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, provided a business review along with key pipeline updates. "We have made tremendous progress at Hillstream over the past year culminating in our successful $15 million IPO with a NASDAQ listing a month ago," stated Randy Milby, Hillstream's Chief Executive Officer, "Our deep roots in scientific innovation and discovery over the past decade, has allowed us to build tailor-made multi-omics ferroptotic datasets across multiple oncologic diseases to power discovery campaigns which leverage our Quatramer™ tumor-targeting platform thus bringing unprecedented therapeutics to patients suffering from devastating cancers.

Hillstream BioPharma Provides Business Review with Key Pipeline Updates

R&D Day on Thursday February 24, 2022 at 8:00 am ET to highlight emerging pipeline assets and anticipated milestones Business Review on Monday February 14, 2022 to highlight key program developments BRIDGEWATER, NJ / ACCESSWIRE / February 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022. R&D Day: Thursday February 24, 2022 at 8:00 am ET - Highlight emerging pipeline assets and anticipated milestones Business Review: Monday February 14, 2022 - Highlight key program developments About Hillstream BioPharma Inc. Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers.

SAVE THE DATES: Hillstream BioPharma Announces R&D Day on February 24, 2022 and Business Review on Monday February 14, 2022

BRIDGEWATER, NJ / ACCESSWIRE / February 1, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced that an abstract highlighting the progress of the Quatramer-based dual-targeted HDAC6/PI3K-delta inhibitor, HSB-510 , has been scheduled for presentation in a Poster Session at the 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans, Louisiana and will be published in the online Proceedings of the AACR. The complete title and text of the abstract will be posted to the AACR Online itinerary planner at 4:30 PM ET on Tuesday March 8, 2022.

Hillstream BioPharma Announces Acceptance of Abstract at AACR 2022 Annual Meeting Highlighting HSB-510, a Novel Quatramer-based, First-in-Class Dual Inhibitor of HDAC6 and PI3K-delta Downregulating c-myc Expression

Collaboration Aims to Identify Novel Chemogenetic Biomarker Profile of HSB-1216 for Solid Tumors Using CRISPR Mediated Genome Editing to Uncover Novel Targets and Gene Regulatory Networks in Ferroptosis / Iron Mediated Cell Death (IMCD) Pathways Further Elucidate the Mechanism of Action of HSB-1216 in Drug Resistance Tumors using CRISPR and Computational Approaches BRIDGEWATER, NJ / ACCESSWIRE / January 26, 2022 / Hillstream BioPharma, Inc. (Nasdaq:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers, today announced a collaboration with University of Massachusetts Chan Medical School to determine the chemogenetic interactions of HSB-1216, which utilizes the Company's novel Quatramer technology, to further advance The Hillstream Ferroptomic Atlas for development of novel targets, gene regulatory networks and biomarkers. The study will be a collaboration between Hillstream and Michael J.

Hillstream BioPharma and University of Massachusetts Chan Medical School Announce Research Collaboration using CRISPR and Computational Approaches to Advance The Hillstream Ferroptomic Atlas

News for Hillstream Biopharma Stock (HILS)